×
Spok Holdings (SPOK) posted a modest gain of roughly 3.5% over the trailing 30-day period, moving from about $10.36 to near $10.72. The company remains a debt-free, cash-generative healthcare communications provider with an annual dividend of $1.25 per share, implying a yield above 10%.
EVERTEC ( EVTC ) is a growing payments and transaction-processing business expanding across Latin America, while Spok Holdings ( SPOK ) is a healthcare-communications company managing a shrinking legacy paging business alongside a growing software platform. EVERTEC has posted double-digit revenue growth and received analyst target increases in recent weeks, whereas Spok's recent profit surge was driven largely by a one-time spectrum sale rather than organic demand.
Tickeron AI Verdict: DOCN is the favored ticker in this comparison, reflecting a more consistent, tradable trend and superior relative momentum versus WEAV . DOCN (DigitalOcean Holdings) is an AI-native cloud platform posting accelerating revenue growth, while WEAV (Weave Communications) is a vertical software provider that has been taken private.
RIOT (Riot Platforms) is a Bitcoin-mining operator rapidly pivoting toward artificial intelligence (AI) and high-performance computing (HPC) data centers, while VEEV (Veeva Systems) is a profitable cloud software leader serving the life sciences industry. Riot's stock has been lifted by a record, roughly $28 billion data-center lease at its Corsicana campus and a nuclear power partnership, while Veeva's momentum stems from steady subscription growth and a deepening AI product lineup.
Veeva Systems ( VEEV ) is a large-cap, profitable life sciences software leader, while Phreesia ( PHR ) is a smaller healthcare engagement and payments platform only recently reaching sustained profitability. Recent relative performance has diverged sharply: VEEV has rallied strongly on AI product momentum, while PHR has been pressured by reduced revenue visibility in its Network Solutions segment.
The central $345 stock price target is the arithmetic mean of 12 verified, current analyst price targets published in November 2026, and it sits roughly 31% above the latest market price. Veeva Systems Inc. (VEEV) last traded near $262.92, so the target requires a substantial advance of about 31% from current levels.
Veeva Systems is scheduled to report results for its fiscal 2027 third quarter (the three months ended October 31, 2026) after market close on December 3, 2026. Wall Street consensus points to adjusted earnings of roughly $2.34 per share on revenue near $935 million, versus $2.04 per share and $811 million in the year-ago quarter.
CleanSpark (CLSK) and Veeva Systems (VEEV) operate in entirely different markets: CLSK is pivoting from Bitcoin mining into AI data centers, while VEEV is a profitable cloud-software leader for life sciences. VEEV has delivered consistent, profitable revenue growth and strong recent momentum, whereas CLSK is in a capital-intensive transition marked by negative adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) and elevated volatility.
Tickeron AI Verdict: VEEV is the favored ticker in this comparison, reflecting stronger trend consistency, more stable fundamentals, and positive relative momentum compared with COIN . COIN (Coinbase Global) remains a high-beta, crypto-linked exchange whose revenue and earnings quality have come under pressure as trading volumes softened.
VEEV is a large-cap life sciences cloud software leader with roughly $50 billion in market capitalization, while WAY is a smaller healthcare payments software provider valued near $5.5 billion, placing them in very different stages of scale and maturity. Recent momentum has diverged sharply: VEEV has posted strong gains over recent months, while WAY shares retreated after softer forward guidance despite solid quarterly results.
ONMD climbed +5.84%, or +$0.26, to $4.71 during Thursday's regular session, rebounding from the prior close of $4.45. No verified news or fundamental catalyst found; the bounce is likely technical, consistent with a snap-back after the prior session's -10.10% slide and a stock that has now reversed direction repeatedly in recent weeks.
BTSGU fell to $215.57 from a prior close of $224.90 on Nov. 18, a -4.15% decline, during Thursday's regular session. The 6.75% tangible equity unit slid alongside BrightSpring's common stock (BTSG), which dropped -5.7% as healthcare selling extended to a third session after CMS's proposed CRUSH anti-fraud rule, which expands Medicare and Medicaid audits with retroactive clawbacks, hit providers and insurers.
Claritev (CTEV) dropped -6.64% to $20.82 from the prior close of $22.30, with the decline occurring during Thursday's regular session. No verified news or fundamental catalyst found; the slide likely reflects sustained profit-taking after the +42% post-earnings run to $28.67, consistent with a stock that averages a ~3.9% absolute daily move.
BTSGU ticked up +$1.75, or +0.76%, to $230.79 from Tuesday's close of $229.04, with the gain booked during Wednesday's regular session. No verified news or fundamental catalyst found: prints in these 6.75% tangible equity units are scattered, so the move is likely thin order-book price discovery — the instrument has averaged a 2.1% absolute daily swing over the last 80 sessions, nearly three times today's move.
GoodRx Holdings is expected to report its third-quarter 2026 results around mid-November 2026, covering the three months ended September 30, 2026. Wall Street consensus calls for earnings of roughly $0.08 per share on revenue near $202 million , compared with $0.08 per share on $196.0 million in the year-ago quarter.
The central target of $4.00 is the arithmetic mean of 13 verified analyst price targets, rounded from a calculated average of roughly $3.97 per share. At a recent price near $3.47, reaching $4.00 would require a gain of about 15%, a modest move relative to the stock's wide trading range.
So-Young International (NASDAQ: SY) is expected to report its third-quarter 2026 results around November 23, 2026, before U.S. markets open, though the date has not yet been officially confirmed. Consensus estimates point to a loss of roughly $0.05 per ADS (American Depositary Share) on revenue of about $75.9 million, reflecting continued rapid top-line expansion alongside a still-narrowing bottom line.
The central $7.30 stock price target is the arithmetic mean of two verified 12-month analyst price targets, rounded from an underlying mean near $7.30. At a recent price near $1.97, reaching $7.30 would require a gain of roughly 270%, a very large move even by small-cap standards.
Multi-condition expansion is the central growth catalyst — migration into Migraine Care and Gastrointestinal (GI) Care (following the Cylinder Health acquisition) could meaningfully widen the company's addressable market beyond its core musculoskeletal (MSK) business. Strategic positioning — Hinge Health's AI-driven, employer- and health-plan-centric platform benefits from high retention and a recurring revenue model, supporting durable medium-term growth.
Hinge Health shares jumped +4.85% to $120.99 during Monday's regular session, up from Friday's close of $115.39, moving back toward the 52-week high of $126.40. No verified news or fundamental catalyst found: no fresh release, filing or analyst action explains a move of this size, so the gain is likely a rebound after Friday's -4.6% slide from that high — today's move is about 2.4x the stock's 2.0% average absolute daily change over the last 60 sessions.